Pediatric ulcerative colitis data on Omvoh could extend Lilly's investment case
FROM THE WIRE · FINANCE.YAHOO.COM
Eli Lilly reported one year Phase 3 SHINE-2 data showing Omvoh achieved its primary endpoint in pediatric ulcerative colitis, with 50% of Week 12 responders aged 6 to 17 in clinical remission at Week 52 and a safety profile consistent with adults. The trial enrolled a high…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPhase 3 pediatric data could extend Lilly's bowel disease franchise if regulators approve a label.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Phase 3 SHINE-2 study met its primary endpoint with Omvoh in pediatric ulcerative colitis.
- 0250% of Week 12 responders aged 6 to 17 were in clinical remission at Week 52.
- 03The safety profile was consistent with adults.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets